SR-123781A is a synthetic hexadecasaccharide Factor IIa and Xa antagonist. It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary syndromes (ACS).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Apixaban | Apixaban may increase the anticoagulant activities of SR-123781A. |
| Dabigatran etexilate | Dabigatran etexilate may increase the anticoagulant activities of SR-123781A. |
| Dasatinib | The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with SR-123781A. |
| Deferasirox | The risk or severity of gastrointestinal bleeding can be increased when SR-123781A is combined with Deferasirox. |
| Ursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when SR-123781A is combined with Ursodeoxycholic acid. |
| Glycochenodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when SR-123781A is combined with Glycochenodeoxycholic Acid. |
| Cholic Acid | The risk or severity of bleeding and bruising can be increased when SR-123781A is combined with Cholic Acid. |
| Glycocholic acid | The risk or severity of bleeding and bruising can be increased when SR-123781A is combined with Glycocholic acid. |
| Deoxycholic acid | The risk or severity of bleeding and bruising can be increased when SR-123781A is combined with Deoxycholic acid. |
| Taurocholic acid | The risk or severity of bleeding and bruising can be increased when SR-123781A is combined with Taurocholic acid. |
| Obeticholic acid | The risk or severity of bleeding and bruising can be increased when SR-123781A is combined with Obeticholic acid. |
| Chenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when SR-123781A is combined with Chenodeoxycholic acid. |
| Taurochenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when SR-123781A is combined with Taurochenodeoxycholic acid. |
| Tauroursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when SR-123781A is combined with Tauroursodeoxycholic acid. |
| Bamet-UD2 | The risk or severity of bleeding and bruising can be increased when SR-123781A is combined with Bamet-UD2. |
| Dehydrocholic acid | The risk or severity of bleeding and bruising can be increased when SR-123781A is combined with Dehydrocholic acid. |
| Hyodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when SR-123781A is combined with Hyodeoxycholic Acid. |
| Edoxaban | The risk or severity of bleeding can be increased when Edoxaban is combined with SR-123781A. |
| Ibrutinib | The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with SR-123781A. |
| Obinutuzumab | The risk or severity of bleeding and hemorrhage can be increased when SR-123781A is combined with Obinutuzumab. |
| Rivaroxaban | SR-123781A may increase the anticoagulant activities of Rivaroxaban. |
| Sugammadex | The risk or severity of bleeding and hemorrhage can be increased when SR-123781A is combined with Sugammadex. |
| Tibolone | Tibolone may increase the anticoagulant activities of SR-123781A. |
| Tipranavir | The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with SR-123781A. |
| Urokinase | Urokinase may increase the anticoagulant activities of SR-123781A. |
| Vitamin E | Vitamin E may increase the anticoagulant activities of SR-123781A. |
| Vorapaxar | The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with SR-123781A. |
| Ginkgo biloba | Ginkgo biloba may increase the anticoagulant activities of SR-123781A. |
| Ifosfamide | The risk or severity of bleeding can be increased when Ifosfamide is combined with SR-123781A. |
| Quinine | The therapeutic efficacy of SR-123781A can be increased when used in combination with Quinine. |
| Quinidine | The therapeutic efficacy of SR-123781A can be increased when used in combination with Quinidine. |
| Tamoxifen | The risk or severity of bleeding can be increased when Tamoxifen is combined with SR-123781A. |
| Toremifene | The risk or severity of bleeding can be increased when Toremifene is combined with SR-123781A. |
| Pentoxifylline | The therapeutic efficacy of SR-123781A can be increased when used in combination with Pentoxifylline. |
| Pentosan polysulfate | Pentosan polysulfate may increase the anticoagulant activities of SR-123781A. |
| Levocarnitine | The therapeutic efficacy of SR-123781A can be increased when used in combination with Levocarnitine. |
| Diethylstilbestrol | Diethylstilbestrol may decrease the anticoagulant activities of SR-123781A. |
| Chlorotrianisene | Chlorotrianisene may decrease the anticoagulant activities of SR-123781A. |
| Conjugated estrogens | Conjugated estrogens may decrease the anticoagulant activities of SR-123781A. |
| Mestranol | The risk or severity of adverse effects can be increased when Mestranol is combined with SR-123781A. |
| Estriol | Estriol may decrease the anticoagulant activities of SR-123781A. |
| Estrone sulfate | Estrone sulfate may decrease the anticoagulant activities of SR-123781A. |
| Quinestrol | Quinestrol may decrease the anticoagulant activities of SR-123781A. |
| Hexestrol | Hexestrol may decrease the anticoagulant activities of SR-123781A. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of SR-123781A. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of SR-123781A. |
| Polyestradiol phosphate | Polyestradiol phosphate may decrease the anticoagulant activities of SR-123781A. |
| Esterified estrogens | Esterified estrogens may decrease the anticoagulant activities of SR-123781A. |
| Zeranol | Zeranol may decrease the anticoagulant activities of SR-123781A. |
| Equol | Equol may decrease the anticoagulant activities of SR-123781A. |
| Methallenestril | Methallenestril may decrease the anticoagulant activities of SR-123781A. |
| Epimestrol | Epimestrol may decrease the anticoagulant activities of SR-123781A. |
| Moxestrol | Moxestrol may decrease the anticoagulant activities of SR-123781A. |
| Estradiol acetate | Estradiol acetate may decrease the anticoagulant activities of SR-123781A. |
| Estradiol benzoate | Estradiol benzoate may decrease the anticoagulant activities of SR-123781A. |
| Estradiol cypionate | Estradiol cypionate may decrease the anticoagulant activities of SR-123781A. |
| Estradiol valerate | Estradiol valerate may decrease the anticoagulant activities of SR-123781A. |
| Biochanin A | Biochanin A may decrease the anticoagulant activities of SR-123781A. |
| Formononetin | Formononetin may decrease the anticoagulant activities of SR-123781A. |
| Limaprost | The risk or severity of adverse effects can be increased when Limaprost is combined with SR-123781A. |
| Icosapent | The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with SR-123781A. |
| Mesalazine | The risk or severity of bleeding can be increased when Mesalazine is combined with SR-123781A. |
| Indomethacin | The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with SR-123781A. |
| Nabumetone | The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with SR-123781A. |
| Ketorolac | The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with SR-123781A. |
| Tenoxicam | The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with SR-123781A. |
| Celecoxib | The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with SR-123781A. |
| Tolmetin | The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with SR-123781A. |
| Rofecoxib | The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with SR-123781A. |
| Piroxicam | The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with SR-123781A. |
| Fenoprofen | The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with SR-123781A. |
| Valdecoxib | The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with SR-123781A. |
| Diclofenac | The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with SR-123781A. |
| Sulindac | The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with SR-123781A. |
| Flurbiprofen | The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with SR-123781A. |
| Etodolac | The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with SR-123781A. |
| Mefenamic acid | The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with SR-123781A. |
| Naproxen | The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with SR-123781A. |
| Sulfasalazine | The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with SR-123781A. |
| Phenylbutazone | The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with SR-123781A. |
| Meloxicam | The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with SR-123781A. |
| Carprofen | The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with SR-123781A. |
| Diflunisal | The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with SR-123781A. |
| Salicylic acid | The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with SR-123781A. |
| Meclofenamic acid | The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with SR-123781A. |
| Oxaprozin | The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with SR-123781A. |
| Ketoprofen | The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with SR-123781A. |
| Balsalazide | The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with SR-123781A. |
| Olsalazine | The risk or severity of bleeding can be increased when Olsalazine is combined with SR-123781A. |
| Lumiracoxib | The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with SR-123781A. |
| Magnesium salicylate | The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with SR-123781A. |
| Salsalate | The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with SR-123781A. |
| Choline magnesium trisalicylate | The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with SR-123781A. |
| Antrafenine | The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with SR-123781A. |
| Aminophenazone | The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with SR-123781A. |
| Antipyrine | The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with SR-123781A. |
| Tiaprofenic acid | The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with SR-123781A. |
| Etoricoxib | The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with SR-123781A. |
| Taxifolin | The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with SR-123781A. |
| Oxyphenbutazone | The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with SR-123781A. |